Licensing Synthetic Biology Patents.
1. Introduction to Licensing Synthetic Biology Patents
Synthetic biology is an interdisciplinary field combining biology, engineering, and computer science to design or reprogram organisms for useful purposes. Patents in synthetic biology often cover:
Engineered DNA sequences
Modified organisms or microbes
Gene editing tools (like CRISPR-based systems)
Biological circuits or biosensors
Licensing allows patent holders to permit others to use their patented inventions under agreed terms, which is critical in synthetic biology because:
Research often involves combining multiple patented technologies.
Licensing reduces litigation risk.
Collaboration accelerates innovation and commercialization.
Licensing can be exclusive (only one licensee) or non-exclusive (multiple licensees). It may also involve field restrictions, royalties, or milestone payments.
2. Key Legal Principles in Synthetic Biology Patent Licensing
Patent eligibility – The invention must be novel, non-obvious, and useful. In synthetic biology, courts often evaluate whether the claimed invention is a naturally occurring sequence or an engineered one.
Doctrine of Exhaustion – Once a patented item is sold, the patent holder’s rights may be exhausted in that context.
Compulsory Licensing – Governments may allow use of a patent without the patent holder’s consent in certain public interest scenarios (rare in synthetic biology).
Antitrust Considerations – Exclusive licenses should not restrict competition unfairly.
3. Significant Case Laws in Synthetic Biology and Related Biotechnology Licensing
Here, I’ll explain more than four cases with detailed reasoning:
Case 1: Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013)
Facts:
Myriad Genetics patented isolated DNA sequences of the BRCA1 and BRCA2 genes, which are linked to breast and ovarian cancer.
The Association for Molecular Pathology challenged the patents, arguing genes are naturally occurring and cannot be patented.
Outcome:
The Supreme Court held that naturally occurring DNA sequences, even if isolated, are not patentable, but complementary DNA (cDNA), which is synthetic, is patentable.
Relevance to Licensing:
Patents must cover synthetic or modified sequences to be enforceable. Licensing agreements must distinguish between naturally occurring genes and engineered sequences.
For example, a company cannot claim royalties on naturally occurring genes but can license synthetic constructs.
Case 2: Amgen Inc. v. Sanofi, 987 F.3d 1080 (Fed. Cir. 2021)
Facts:
Amgen owned patents for biologic drugs targeting PCSK9, a protein involved in cholesterol regulation.
Sanofi developed a similar drug, and Amgen claimed patent infringement.
Outcome:
The court emphasized enablement and written description: patents must fully describe how to make and use the invention.
Amgen’s patents were upheld, but with narrowed claims.
Relevance to Licensing:
When licensing synthetic biology patents, licensees must receive sufficient technical disclosure to legally use the technology.
Licensing agreements often include detailed protocols and know-how, not just patent rights.
Case 3: Diamond v. Chakrabarty, 447 U.S. 303 (1980)
Facts:
Chakrabarty genetically engineered a bacterium capable of breaking down crude oil.
The USPTO initially rejected the patent, claiming living organisms cannot be patented.
Outcome:
Supreme Court ruled genetically modified organisms are patentable because they are not naturally occurring.
Relevance to Licensing:
Synthetic biology patents on engineered organisms can be licensed commercially.
This case laid the foundation for companies like Genentech and synthetic biology startups to license engineered microbes for biofuels, medicine, or industrial enzymes.
Case 4: Harvard College v. Canada (Commissioner of Patents), 2002 FCA 241
Facts:
Harvard held a patent for the OncoMouse, a genetically engineered mouse used in cancer research.
Canadian courts had to decide whether the patent was valid and what rights the patent holder had.
Outcome:
The court granted the patent but limited the scope regarding commercial breeding.
Emphasized balancing innovation incentives with public research needs.
Relevance to Licensing:
Licensing animal or microbial models often includes restrictions on research vs. commercial use.
Licenses can differentiate between academic/non-profit use and commercial exploitation.
Case 5: Monsanto Canada Inc. v. Schmeiser, [2004] 1 S.C.R. 902
Facts:
Monsanto patented genetically modified (GM) canola resistant to herbicides.
Farmer Schmeiser unknowingly grew crops containing Monsanto’s patented genes.
Outcome:
Supreme Court of Canada ruled patent infringement occurs even without intent, emphasizing the broad scope of biotech patents.
Relevance to Licensing:
Licensing agreements must clearly define scope and field of use to avoid accidental infringement.
Royalties, sublicensing rights, and compliance obligations are critical in synthetic biology.
Case 6: Wyeth v. Levine, 555 U.S. 555 (2009) – Indirectly Relevant
Facts:
Concerned patent and FDA regulatory compliance for a drug delivery system.
Outcome:
Reinforced that patent licensing interacts with regulatory approval.
Relevance to Synthetic Biology Licensing:
Many synthetic biology inventions (gene therapies, engineered cells) require regulatory approval. Licenses may include clauses regarding regulatory compliance, liability, and indemnification.
4. Licensing Considerations in Synthetic Biology
From these cases, we see key licensing strategies:
Scope Definition:
Exclusive vs. non-exclusive licenses
Field of use (research, commercial, diagnostic)
Technical Disclosure:
Ensure the licensee has sufficient information to use the invention (enablement).
Regulatory Compliance:
License agreements often include obligations to follow FDA, EPA, or international regulations.
Royalties and Milestones:
Often tied to product development, sales, or clinical approval.
Freedom-to-Operate:
Synthetic biology products often involve multiple overlapping patents; licensing must account for patent stacking.
Summary Table of Key Cases
| Case | Year | Jurisdiction | Key Principle for Synthetic Biology Licensing |
|---|---|---|---|
| Myriad Genetics | 2013 | US | Natural DNA not patentable; synthetic sequences are |
| Amgen v. Sanofi | 2021 | US | Enablement and written description critical |
| Diamond v. Chakrabarty | 1980 | US | Genetically engineered organisms patentable |
| Harvard College v. Canada | 2002 | Canada | Patents on engineered animals valid, but scope limited |
| Monsanto v. Schmeiser | 2004 | Canada | Inadvertent use can still infringe; scope clarity vital |
| Wyeth v. Levine | 2009 | US | Licensing interacts with regulatory compliance |
RELATED Blog
comments